Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.
Pharmacological treatment of alcohol use disorder. Scientific evidence / Perciballi, R., Rotondo, C., Capriglione, I., Iannuzzi, S., Attilia, M.L., Vitali, M., Scamporrino, M.C.M., Fiore, M., Ceccanti, M., Addolorato, G., Aliotta, V., Barletta, G., Battaglia, E., Battagliese, G., Carito, V., Casciani, O., Casella, P., Cesarini, F., Cibin, M., Ciccarelli, R., et al.. - In: RIVISTA DI PSICHIATRIA. - ISSN 0035-6484. - 53:3(2018), pp. 123-127. [10.1708/2925.29414]
Pharmacological treatment of alcohol use disorder. Scientific evidence
Perciballi R.Secondo
;Rotondo C.;Capriglione I.;Iannuzzi S.;Attilia M. L.;Vitali M.;SCAMPORRINO, MARIA CONCETTA MARCELLA;Ceccanti M.;Battagliese G.;Cesarini F.;Ciccarelli R.;Ciolli P.;Coriale G.;Ferraguti G.;Fiorentino D.;Gencarelli S.;Greco A.;La Torre G.;Ledda R.;Macri S.;Messina M. P.;Pascale E.;Pisciotta F.;Fabio AttiliaPrimo
;Giovanni Alessandrini
2018
Abstract
Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Attilia_Pharmacological_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
98.19 kB
Formato
Adobe PDF
|
98.19 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
